Targeting Interleukin-1 in Heart Failure and Inflammatory Heart Disease

Overview

Journal Curr Heart Fail Rep

Publisher Current Science

Date 2014 Oct 16

PMID 25315037

Citations 48

Authors

Benjamin W Van Tassell

Juan M Valle Raleigh

Antonio Abbate

Affiliations

Soon will be listed here.

Abstract

Heart failure (HF) is a clinical syndrome characterized by dyspnea, fatigue, and poor exercise capacity due to insufficient cardiac function. HF represents the leading cause of hospitalization among adult patients over 65 years of age. Neurohormonal blockade has improved clinical outcomes; however, HF incidence continues to rise, suggesting an urgent need to develop novel drugs that target a different pathophysiological paradigm. Inflammation plays a central role in many cardiovascular diseases. Interleukin-1 (IL-1), a prototypical proinflammatory cytokine, is upregulated in HF and associated with worse prognosis. Preclinical models suggest a beneficial effect of IL-1 blockade, and pilot clinical trials are currently underway to evaluate the role of IL-1 blockade to reduce inflammation, ameliorate ventricular remodeling, and improve exercise capacity in patients with HF.

Citing Articles

Hydrogen gas inhalation prior to high-intensity training reduces attenuation of nitric oxide bioavailability in male rugby players.

Zhao Y, Li C, Zhou S, Xu Z, Huang X, Wen L PeerJ. 2024; 12:e18503.

PMID: 39703911 PMC: 11657200. DOI: 10.7717/peerj.18503.

The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease.

Zhang H, Dhalla N Int J Mol Sci. 2024; 25(2).

PMID: 38256155 PMC: 10817020. DOI: 10.3390/ijms25021082.

Targeting Key Inflammatory Mechanisms Underlying Heart Failure: A Comprehensive Review.

Papamichail A, Kourek C, Briasoulis A, Xanthopoulos A, Tsougos E, Farmakis D Int J Mol Sci. 2024; 25(1).

PMID: 38203681 PMC: 10778956. DOI: 10.3390/ijms25010510.

Research progress on the activation mechanism of NLRP3 inflammasome in septic cardiomyopathy.

Wen Y, Liu Y, Liu W, Liu W, Dong J, Liu Q Immun Inflamm Dis. 2023; 11(10):e1039.

PMID: 37904696 PMC: 10549821. DOI: 10.1002/iid3.1039.

Central and Peripheral Inflammation: A Common Factor Causing Addictive and Neurological Disorders and Aging-Related Pathologies.

Escobar A, Bonansco C, Cruz G, Dagnino-Subiabre A, Fuenzalida M, Negron I Int J Mol Sci. 2023; 24(12).

PMID: 37373230 PMC: 10298583. DOI: 10.3390/ijms241210083.

References

Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P . Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014; 7(4):619-28. DOI: 10.1161/CIRCIMAGING.113.001193. View

Lane J, Neumann D, Herskowitz A, Rose N . Interleukin 1 or tumor necrosis factor can promote Coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med. 1992; 175(4):1123-9. PMC: 2119174. DOI: 10.1084/jem.175.4.1123. View

Abbate A, Kontos M, Grizzard J, Biondi-Zoccai G, Van Tassell B, Robati R . Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010; 105(10):1371-1377.e1. DOI: 10.1016/j.amjcard.2009.12.059. View

Balady G, Arena R, Sietsema K, Myers J, Coke L, Fletcher G . Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010; 122(2):191-225. DOI: 10.1161/CIR.0b013e3181e52e69. View

Ridker P, Thuren T, Zalewski A, Libby P . Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011; 162(4):597-605. DOI: 10.1016/j.ahj.2011.06.012. View

Shah S, Marcus G, Gerber I, McKeown B, Vessey J, Jordan M . High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. J Card Fail. 2006; 12(1):61-5. DOI: 10.1016/j.cardfail.2005.08.003. View

Yndestad A, Damas J, Oie E, Ueland T, Gullestad L, Aukrust P . Systemic inflammation in heart failure--the whys and wherefores. Heart Fail Rev. 2006; 11(1):83-92. DOI: 10.1007/s10741-006-9196-2. View

Dinarello C . Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011; 117(14):3720-32. PMC: 3083294. DOI: 10.1182/blood-2010-07-273417. View

Zhu J, Zhang J, Xiang D, Zhang Z, Zhang L, Wu M . Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol. 2010; 643(2-3):247-53. DOI: 10.1016/j.ejphar.2010.06.024. View

10.

Lim B, Choe S, Shin J, Ho S, Kim J, Yu S . Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation. 2002; 105(11):1278-81. View

11.

Toldo S, Kannan H, Bussani R, Anzini M, Sonnino C, Sinagra G . Formation of the inflammasome in acute myocarditis. Int J Cardiol. 2014; 171(3):e119-21. DOI: 10.1016/j.ijcard.2013.12.137. View

12.

Paulus W, Tschope C, Sanderson J, Rusconi C, Flachskampf F, Rademakers F . How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007; 28(20):2539-50. DOI: 10.1093/eurheartj/ehm037. View

13.

Toldo S, Mezzaroma E, OBrien L, Marchetti C, Seropian I, Voelkel N . Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol. 2014; 306(7):H1025-31. PMC: 3962640. DOI: 10.1152/ajpheart.00795.2013. View

14.

Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo J . Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996; 183(3):949-58. PMC: 2192364. DOI: 10.1084/jem.183.3.949. View

15.

Abbate A, Van Tassell B, Seropian I, Toldo S, Robati R, Varma A . Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail. 2010; 12(4):319-22. DOI: 10.1093/eurjhf/hfq017. View

16.

Abbate A, Salloum F, Van Tassell B, Vecile E, Toldo S, Seropian I . Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS One. 2011; 6(11):e27923. PMC: 3225370. DOI: 10.1371/journal.pone.0027923. View

17.

Toldo S, Mezzaroma E, Bressi E, Marchetti C, Carbone S, Sonnino C . Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J Cardiovasc Pharmacol. 2014; 64(1):1-6. DOI: 10.1097/FJC.0000000000000106. View

18.

Abbate A, Canada J, Van Tassell B, Wise C, Dinarello C . Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity?. Int J Cardiol. 2014; 171(3):e125-6. DOI: 10.1016/j.ijcard.2013.12.078. View

19.

Van Tassell B, Toldo S, Mezzaroma E, Abbate A . Targeting interleukin-1 in heart disease. Circulation. 2013; 128(17):1910-23. PMC: 3938092. DOI: 10.1161/CIRCULATIONAHA.113.003199. View

20.

Van Tassell B, Seropian I, Toldo S, Mezzaroma E, Abbate A . Interleukin-1β induces a reversible cardiomyopathy in the mouse. Inflamm Res. 2013; 62(7):637-40. DOI: 10.1007/s00011-013-0625-0. View